Glenmark receives DCGI approval to launch oncology drug BRUKINSA in India
Zanubrutinib will be marketed in India under the brand name BRUKINSA, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).
Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA. This extensive clinical program underscores BRUKINSA's proven efficacy, strong safety profile, and broad therapeutic value.
The introduction of BRUKINSA brings an innovative treatment option at a time when India continues to face a significant burden from serious and difficult-to-treat haematological malignancies. According to various sources, someone in India is diagnosed with blood cancer every five minutes, and an estimated 70,000 people die from the disease each year. BRUKINSA addresses a critical unmet need with its differentiated pharmacological profile, demonstrating high response rates and durable disease control across multiple B-cell malignancies as shown in pivotal clinical trials. BRUKINSA's flexible dosing regimen (once or twice daily) supports personalized care.1 In the head-to-head ALPINE study in relapsed/refractory chronic lymphocytic leukemia, BRUKINSA demonstrated a lower rate of serious cardiac events (1.9% vs. 7.7%) and fewer treatment discontinuations due to cardiac issues (0.3% vs. 4.3%) compared with ibrutinib.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Is your makeup safe? Govt may soon ban mercury-based cosmetics in India
The Government of India is considering a ban on mercury-based cosmetics following a recommendation from a Drugs Controller General of India (DCGI) subcommittee, Mint reported, citing official documents. The move aims to identify and phase out mercury-containing products from India's ₹20-billion cosmetics market, including online platforms, and align with international safety standards. Mercury in cosmetics: Why you should be concerned Ever wondered what's really inside your favourite cosmetic products? You might want to take a closer look at the label—because the toxic metal mercury could be hiding in your eyeliner or skin cream. Mercury isn't just harmful to the skin; it's a health hazard that can seep into your bloodstream and cause long-term damage. It can cause skin rashes, discolouration, thinning of the skin, and even permanent scarring. According to the Mint report, mercury-based products such as skin-lightening creams, anti-ageing solutions, and some eye makeup items are particularly risky. These often deliver quick, 'miracle' results that tempt consumers—especially the young—but the long-term effects can be deeply damaging. What do the current rules say about mercury in makeup? Currently, Indian regulations permit limited mercury use. According to Rule 39(5) of the Cosmetics Rules, 2020, cosmetics meant for the eye area may contain up to 70 parts per million (0.007 per cent) of mercury as a preservative. For all other cosmetics, mercury should not exceed 1 ppm. However, the DCGI's subcommittee is advocating a stricter standard—a complete ban on the manufacture, import, and export of any cosmetic containing more than 1 ppm of mercury. This would bring India in line with the Minamata Convention, which seeks to eliminate mercury from consumer products globally. Self-declaration, surprise tests planned for compliance Cosmetic companies may soon be required to self-declare whether they use mercury. This will be followed by surprise lab tests and random sampling by regulators such as the Central Drugs Standard Control Organisation (CDSCO). An official quoted by Mint said, 'The logical step is to require manufacturers to self-declare their use of mercury, propose alternative formulations, and give them a strict deadline for phasing out mercury.' How cosmetic brands are reacting Some companies have already stated their position. L'Oréal India told Mint it does not intentionally use mercury in any of its products worldwide, and that its offerings meet the highest safety standards. Other leading brands such as Lakmé, Maybelline, Sugar Cosmetics, and Nykaa did not respond to media queries. A government official noted, 'Wherever there is a casual approach in handling toxic substances, the risk to human life and the environment is high. The smarter path is to either properly manage toxic substances or stop using them entirely.' Minamata Convention also targets mercury in household items The Mint report noted that mercury-based household products—including certain medical devices—have been flagged for phase-out under the Minamata Convention. This global agreement aims to reduce human and environmental exposure to mercury. What can consumers do to protect themselves?
Mint
14 hours ago
- Mint
What's that in your eye? Govt asked to ban mercury-based cosmetics
New Delhi: The Centre is deliberating a crack-down on cosmetic makers using mercury in their formulations after a government committee recommended a ban, according to officials and documents reviewed by Mint. A panel set by the Drugs Controller General of India (DCGI) has recommended that the use of mercury in cosmetic formulations be banned, documents showed. The Centre plans to identify cosmetics containing mercury and phase out their sale from the $20-billion Indian cosmetics market and from online platforms this year. Cosmetic manufacturers will have to provide self-declarations about their products being mercury-free. The products will then be put to rigorous laboratory tests for verification, officials said. A sub-committee established by the DCGI discussed banning the import, export, and manufacture of cosmetics containing over 1 part per million (ppm) of mercury, aligning with the global Minamata Convention—an international treaty designed to protect human health and the environment from the harmful effects of mercury and its compounds. Mercury content is limited under Rule 39 (5) of Cosmetics Rules, 2020. In cosmetics intended for use only in the area of eye, the level of mercury should not exceed 70 parts per million (0.007%), calculated as the metal, as a preservative. In other finished cosmetic products, 'unintentional mercury shall not exceed 1 ppm". The committee was chaired by (Prof) Dr S.N. Bhattacharya of RML Hospital's dermatology department, and included experts from pharmacology, toxicology, the Bureau of Indian Standards (BIS), the Central Drugs Standard Control Organization (CDSCO), and the environment ministry. Mercury is a toxic element that affects both human health and the environment. Products such as skin-lightening creams, 'anti-aging solutions' for freckles and dark spots and certain makeup items are known to contain mercury. 'Mercury use in the formulation of cosmetics has to be stringently discouraged/stopped," the sub-committee recommended, according to minutes of a meeting reviewed by Mint. 'Keeping mercury stocks alive for even 'safe' proportions maintains its trade, creating multiple points for potential environmental contamination during stocking, manufacturing, procuring, and transportation," said a government official familiar with the matter requesting anonymity. 'Any mishap can lead to mercury exposure in the environment which can be harmful to everyone," the official said. 'So, the logical step is to require manufacturers to self-declare their use of mercury, propose alternative formulations, and give them a strict deadline for phasing out mercury. These companies will also be required to give mandatory certification and random testing by the CDSCO by picking samples from the market," said the official. 'The matter was discussed in the Drugs Consultative Committee meeting held recently. Minimata Convention 2023 discourages the use or cosmetics in household products. In fact, mercury thermometer and BP meters were also covered in Minimata Convention. Mercury presence is hazardous for human being. Mostly eye-preparations like eye shadow etc use some mercury content as perseverative. Currently, Indian regulations allow for a certain permissible limit of mercury in some products. A sub-committee was formed to look into this matter," said a second government official who also did not want to be named. The official also noted a clear trend towards phasing out mercury in the medical devices industry. 'Today, we are seeing digital BP meters and thermometers as mercury-based devices being phased out from the medical industry," the official stated. 'Wherever there is a casual approach in the handling of toxic substances, the risk to environmental and human life is high. There is a need for either comprehensive education on proper toxic substance management or, more effectively, the discouragement of mercury use altogether," the first official said. Ruchi Mittal, R&D Head of Kaya Ltd, a chain of skin and hair clinics, emphasized the severe health consequences of mercury in cosmetics. 'Mercury can be absorbed into the bloodstream, leading to internal health issues, autoimmune conditions and potentially irreversible damage to the nervous, immune, renal and developmental systems. This grave risk is why mercury use in cosmetics is already banned in many countries," said Mittal. Queries sent to the health ministry spokesperson and DCGI remained unanswered till press time. Top cosmetic brands available in India include Lakmé, L'Oréal Paris, Maybelline, Sugar Cosmetics, and Nykaa. 'L'Oréal does not intentionally add mercury to any of its products in India or anywhere in the world. L'Oréal is highly committed to consumer safety. All the products we manufacture, distribute and market are in full compliance with regulations, subjected to rigorous evaluation and follow the highest international standards," said a L'Oréal India spokesperson. The other brands mentioned above did not respond to a request for comment till press time. Dr. Sarita Sanke, dermatologist, Apollo Spectra Hospital, Delhi said that in order to implement this initiative effectively, strategies such as the strict monitoring, awareness campaigns and transparent reporting by both manufacturers and regulators should be adopted. Digital market places should adopt robust surveillance to prevent the sale of non-compliant products. 'Mercury in cosmetics may initially give the illusion of fairer, blemish-free skin, but it comes at the cost of long-term damage, including skin thinning, rashes, discoloration, and even permanent scarring."
&w=3840&q=100)
Business Standard
25-06-2025
- Business Standard
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Glenmark Pharmaceuticals share price today: Pharmaceutical major Glenmark Pharmaceuticals shares rose as much as 2.74 per cent to hit an intraday high of ₹1,728 per share on Wednesday, June 25, 2025. Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels. Why did Glenmark Pharmaceuticals share price rise today? Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO). Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies. The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC). The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies. NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said. Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme. Glenamark Pharmaceuticals Q4 results For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent. For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology. With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape. The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index. Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
